Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy
- 7 September 2007
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 360 (4), 772-777
- https://doi.org/10.1016/j.bbrc.2007.06.148
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 22 references indexed in Scilit:
- Leukocyte Recruitment and Vascular Injury in Diabetic NephropathyJournal of the American Society of Nephrology, 2006
- Advanced Glycation End Products Increase Collagen-specific Chaperone Protein in Mouse Diabetic NephropathyOnline Journal of Public Health Informatics, 2004
- Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing miceJCI Insight, 2001
- Role of Monocyte Chemotactic Peptide 1 in Diabetic NephropathyNephron, 2001
- Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout miceCurrent Opinion in Lipidology, 2001
- Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathyKidney International, 2000
- Renin-angiotensin blockade lowers MCP-1 expression in diabetic ratsKidney International, 1999
- Mesangial Matrix Modulation and GlomerulosclerosisNephron Experimental Nephrology, 1999
- Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosisNature, 1998
- The Role of Macrophages in Diabetic GlomerulosclerosisAmerican Journal of Kidney Diseases, 1993